129 related articles for article (PubMed ID: 36599133)
1. Effects of the omega-3 fatty acid DHA on histone and p53 acetylation in diffuse large B cell lymphoma.
Bakhshi TJ; Way T; Muncy B; Georgel PT
Biochem Cell Biol; 2023 Apr; 101(2):172-191. PubMed ID: 36599133
[TBL] [Abstract][Full Text] [Related]
2. Inactivating mutations of acetyltransferase genes in B-cell lymphoma.
Pasqualucci L; Dominguez-Sola D; Chiarenza A; Fabbri G; Grunn A; Trifonov V; Kasper LH; Lerach S; Tang H; Ma J; Rossi D; Chadburn A; Murty VV; Mullighan CG; Gaidano G; Rabadan R; Brindle PK; Dalla-Favera R
Nature; 2011 Mar; 471(7337):189-95. PubMed ID: 21390126
[TBL] [Abstract][Full Text] [Related]
3. CARM1 inhibition reduces histone acetyltransferase activity causing synthetic lethality in CREBBP/EP300-mutated lymphomas.
Veazey KJ; Cheng D; Lin K; Villarreal OD; Gao G; Perez-Oquendo M; Van HT; Stratton SA; Green M; Xu H; Lu Y; Bedford MT; Santos MA
Leukemia; 2020 Dec; 34(12):3269-3285. PubMed ID: 32576962
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of CREBBP expands the germinal center B cell compartment, down-regulates MHCII expression and promotes DLBCL growth.
Hashwah H; Schmid CA; Kasser S; Bertram K; Stelling A; Manz MG; Müller A
Proc Natl Acad Sci U S A; 2017 Sep; 114(36):9701-9706. PubMed ID: 28831000
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of garcinol and curcumin on histone and p53 modifications in tumour cells.
Collins HM; Abdelghany MK; Messmer M; Yue B; Deeves SE; Kindle KB; Mantelingu K; Aslam A; Winkler GS; Kundu TK; Heery DM
BMC Cancer; 2013 Jan; 13():37. PubMed ID: 23356739
[TBL] [Abstract][Full Text] [Related]
6. CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis.
Huang YH; Cai K; Xu PP; Wang L; Huang CX; Fang Y; Cheng S; Sun XJ; Liu F; Huang JY; Ji MM; Zhao WL
Signal Transduct Target Ther; 2021 Jan; 6(1):10. PubMed ID: 33431788
[TBL] [Abstract][Full Text] [Related]
7. Depletion of the transcriptional coactivators CREB-binding protein or EP300 downregulates CD20 in diffuse large B-cell lymphoma cells and impairs the cytotoxic effects of anti-CD20 antibodies.
Scialdone A; Khazaei S; Hasni MS; Lennartsson A; Gullberg U; Drott K
Exp Hematol; 2019 Nov; 79():35-46.e1. PubMed ID: 31669559
[TBL] [Abstract][Full Text] [Related]
8. Histone acetyltransferase-deficient p300 mutants in diffuse large B cell lymphoma have altered transcriptional regulatory activities and are required for optimal cell growth.
Haery L; Lugo-Picó JG; Henry RA; Andrews AJ; Gilmore TD
Mol Cancer; 2014 Feb; 13():29. PubMed ID: 24529102
[TBL] [Abstract][Full Text] [Related]
9. Unique and Shared Epigenetic Programs of the CREBBP and EP300 Acetyltransferases in Germinal Center B Cells Reveal Targetable Dependencies in Lymphoma.
Meyer SN; Scuoppo C; Vlasevska S; Bal E; Holmes AB; Holloman M; Garcia-Ibanez L; Nataraj S; Duval R; Vantrimpont T; Basso K; Brooks N; Dalla-Favera R; Pasqualucci L
Immunity; 2019 Sep; 51(3):535-547.e9. PubMed ID: 31519498
[TBL] [Abstract][Full Text] [Related]
10. Genome-wide CRISPR screens reveal synthetic lethal interaction between CREBBP and EP300 in diffuse large B-cell lymphoma.
Nie M; Du L; Ren W; Joung J; Ye X; Shi X; Ciftci S; Liu D; Wu K; Zhang F; Pan-Hammarström Q
Cell Death Dis; 2021 Apr; 12(5):419. PubMed ID: 33911074
[TBL] [Abstract][Full Text] [Related]
11. KMT2D acetylation by CREBBP reveals a cooperative functional interaction at enhancers in normal and malignant germinal center B cells.
Vlasevska S; Garcia-Ibanez L; Duval R; Holmes AB; Jahan R; Cai B; Kim A; Mo T; Basso K; Soni RK; Bhagat G; Dalla-Favera R; Pasqualucci L
Proc Natl Acad Sci U S A; 2023 Mar; 120(11):e2218330120. PubMed ID: 36893259
[TBL] [Abstract][Full Text] [Related]
12. The CREBBP Acetyltransferase Is a Haploinsufficient Tumor Suppressor in B-cell Lymphoma.
Zhang J; Vlasevska S; Wells VA; Nataraj S; Holmes AB; Duval R; Meyer SN; Mo T; Basso K; Brindle PK; Hussein S; Dalla-Favera R; Pasqualucci L
Cancer Discov; 2017 Mar; 7(3):322-337. PubMed ID: 28069569
[TBL] [Abstract][Full Text] [Related]
13. Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.
Juskevicius D; Jucker D; Klingbiel D; Mamot C; Dirnhofer S; Tzankov A
J Hematol Oncol; 2017 Mar; 10(1):70. PubMed ID: 28302137
[TBL] [Abstract][Full Text] [Related]
14. CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas.
Jiang Y; Ortega-Molina A; Geng H; Ying HY; Hatzi K; Parsa S; McNally D; Wang L; Doane AS; Agirre X; Teater M; Meydan C; Li Z; Poloway D; Wang S; Ennishi D; Scott DW; Stengel KR; Kranz JE; Holson E; Sharma S; Young JW; Chu CS; Roeder RG; Shaknovich R; Hiebert SW; Gascoyne RD; Tam W; Elemento O; Wendel HG; Melnick AM
Cancer Discov; 2017 Jan; 7(1):38-53. PubMed ID: 27733359
[TBL] [Abstract][Full Text] [Related]
15. Evidence for an oncogenic modifier role for mutant histone acetyltransferases in diffuse large B-cell lymphoma.
Haery L; Mussakhan S; Waxman DJ; Gilmore TD
Leuk Lymphoma; 2016 Nov; 57(11):2661-71. PubMed ID: 27003102
[TBL] [Abstract][Full Text] [Related]
16. Inhibitor of CBP Histone Acetyltransferase Downregulates p53 Activation and Facilitates Methylation at Lysine 27 on Histone H3.
Vincek AS; Patel J; Jaganathan A; Green A; Pierre-Louis V; Arora V; Rehmann J; Mezei M; Zhou MM; Ohlmeyer M; Mujtaba S
Molecules; 2018 Aug; 23(8):. PubMed ID: 30072621
[TBL] [Abstract][Full Text] [Related]
17.
García-Ramírez I; Tadros S; González-Herrero I; Martín-Lorenzo A; Rodríguez-Hernández G; Moore D; Ruiz-Roca L; Blanco O; Alonso-López D; Rivas JL; Hartert K; Duval R; Klinkebiel D; Bast M; Vose J; Lunning M; Fu K; Greiner T; Rodrigues-Lima F; Jiménez R; Criado FJG; Cenador MBG; Brindle P; Vicente-Dueñas C; Alizadeh A; Sánchez-García I; Green MR
Blood; 2017 May; 129(19):2645-2656. PubMed ID: 28288979
[TBL] [Abstract][Full Text] [Related]
18. TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis.
Dominguez PM; Ghamlouch H; Rosikiewicz W; Kumar P; Béguelin W; Fontán L; Rivas MA; Pawlikowska P; Armand M; Mouly E; Torres-Martin M; Doane AS; Calvo Fernandez MT; Durant M; Della-Valle V; Teater M; Cimmino L; Droin N; Tadros S; Motanagh S; Shih AH; Rubin MA; Tam W; Aifantis I; Levine RL; Elemento O; Inghirami G; Green MR; Figueroa ME; Bernard OA; Aoufouchi S; Li S; Shaknovich R; Melnick AM
Cancer Discov; 2018 Dec; 8(12):1632-1653. PubMed ID: 30274972
[No Abstract] [Full Text] [Related]
19. Histone regulator KAT2A acts as a potential biomarker related to tumor microenvironment and prognosis of diffuse large B cell lymphoma.
Yu Z; Ding M; Cai Y; Lu T; Chen X; Zhou X; Wang X
BMC Cancer; 2023 Oct; 23(1):934. PubMed ID: 37789275
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic mechanisms of Rubinstein-Taybi syndrome.
Park E; Kim Y; Ryu H; Kowall NW; Lee J; Ryu H
Neuromolecular Med; 2014 Mar; 16(1):16-24. PubMed ID: 24381114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
